UBS Group Lowers Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $2.20

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Free Report) had its price target trimmed by UBS Group from $5.00 to $2.20 in a report published on Tuesday,Benzinga reports. The firm currently has a neutral rating on the stock.

Several other brokerages have also commented on ZNTL. Wedbush reaffirmed a "neutral" rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Guggenheim reduced their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, November 15th. Finally, HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $8.24.

Zentalis Pharmaceuticals Stock Performance

Shares of Zentalis Pharmaceuticals stock traded up $0.10 on Tuesday, reaching $1.76. The stock had a trading volume of 2,814,399 shares, compared to its average volume of 2,900,131. Zentalis Pharmaceuticals has a fifty-two week low of $1.66 and a fifty-two week high of $18.07. The business's 50-day moving average price is $2.97 and its two-hundred day moving average price is $3.29. The stock has a market cap of $125.07 million, a P/E ratio of -0.70 and a beta of 1.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.36. As a group, equities analysts forecast that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Savant Capital LLC bought a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at about $72,000. SG Americas Securities LLC increased its position in shares of Zentalis Pharmaceuticals by 115.6% in the 4th quarter. SG Americas Securities LLC now owns 56,389 shares of the company's stock valued at $171,000 after buying an additional 30,240 shares in the last quarter. Barclays PLC raised its stake in Zentalis Pharmaceuticals by 18.5% during the 3rd quarter. Barclays PLC now owns 75,395 shares of the company's stock worth $277,000 after buying an additional 11,748 shares during the period. XTX Topco Ltd grew its position in shares of Zentalis Pharmaceuticals by 8.7% in the 3rd quarter. XTX Topco Ltd now owns 194,062 shares of the company's stock valued at $714,000 after purchasing an additional 15,597 shares during the period. Finally, Quarry LP acquired a new position in Zentalis Pharmaceuticals in the 3rd quarter worth $55,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.